Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Direct oral anticoagulants (DOACs) and vitamin K antagonists (VKA) are currently prescribed in Switzerland for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). Based on evidence from an observational study, an external applicant requested the FOPH to re-evaluate the use of DOACs for NVAF in Switzerland. The aim of this HTA is to evaluate the efficacy, effectiveness, safety, cost-effectiveness and budgetary impact of DOACs compared to VKAs for the prevention of stroke and other thromboembolic events in patients diagnosed with NVAF.

Last modification 29.04.2022

Top of page


Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Tel. +41 58 469 17 33

Print contact